| First Author | Ahmed S | Year | 2018 |
| Journal | Biochim Biophys Acta Mol Cell Res | Volume | 1865 |
| Issue | 11 Pt A | Pages | 1590-1597 |
| PubMed ID | 30327200 | Mgi Jnum | J:318892 |
| Mgi Id | MGI:6863670 | Doi | 10.1016/j.bbamcr.2018.08.013 |
| Citation | Ahmed S, et al. (2018) The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis. Biochim Biophys Acta Mol Cell Res 1865(11 Pt A):1590-1597 |
| abstractText | We have previously shown that the Ste20-like kinase SLK interacts directly with the LIM domain-binding protein 1, Ldb1. Ldb1 knock down in murine fibroblasts activates SLK and enhances cell migration. To investigate the effect of Ldb1 deletion in ErbB2/HER2-driven tumorigenesis, Ldb1 conditional mice were crossed into MMTV-NIC mice, expressing the Neu oncogene and Cre recombinase from a bi-cistronic transgene. Our results show that Ldb1 is expressed in the mammary epithelium and that deletion of Ldb1 does not impair mammary gland development. Although high levels of Ldb1 can be correlated with poor prognosis in HER2+ breast cancers, Ldb1 ablation does not affect Neu-induced tumor progression in transgenic mice. Surprisingly, Ldb1 deletion did not affect SLK kinase activity in primary tumors or established cell lines. Nevertheless, Ldb1-deficient tumor cells showed enhanced mesenchymal and migratory characteristics in vitro. However, Ldb1-null cells failed to colonize the lungs of wildtype female mice when injected into the tail vein. Together our results show that Ldb1 is dispensable for mammary gland development and Neu-induced tumor progression but required for dissemination at secondary sites. Furthermore, our data also highlight contrasting cell line behaviours observed from in vivo and in vitro assays. |
